Please wait while the formulary information is being retrieved.
Drug overview for OLUMIANT (baricitinib):
Generic name: baricitinib (BAR-i-SYE-ti-nib)
Drug class: Antirheumatic Agents (Biologic DMARDS)
Therapeutic class: Analgesic, Anti-inflammatory or Antipyretic
Baricitinib, a Janus kinase (JAK) inhibitor, is an immunomodulating agent and a disease-modifying antirheumatic drug (DMARD).
No enhanced Uses information available for this drug.
Generic name: baricitinib (BAR-i-SYE-ti-nib)
Drug class: Antirheumatic Agents (Biologic DMARDS)
Therapeutic class: Analgesic, Anti-inflammatory or Antipyretic
Baricitinib, a Janus kinase (JAK) inhibitor, is an immunomodulating agent and a disease-modifying antirheumatic drug (DMARD).
No enhanced Uses information available for this drug.
DRUG IMAGES
- OLUMIANT 2 MG TABLET
The following indications for OLUMIANT (baricitinib) have been approved by the FDA:
Indications:
Adjunct therapy for COVID-19 requiring oxygen or ventilatory support
Alopecia areata
Rheumatoid arthritis
Professional Synonyms:
Adjunct therapy for 2019-nCoV disease requiring oxygen or ventilatory support
Adjunct therapy for SARS-CoV-2 infection requiring oxygen or ventilatory support
Areata alopecia
Arthritis deformans
Arthrosis deformans
Nodose rheumatism
Rheumatic arthritis
Rheumatic gout
Indications:
Adjunct therapy for COVID-19 requiring oxygen or ventilatory support
Alopecia areata
Rheumatoid arthritis
Professional Synonyms:
Adjunct therapy for 2019-nCoV disease requiring oxygen or ventilatory support
Adjunct therapy for SARS-CoV-2 infection requiring oxygen or ventilatory support
Areata alopecia
Arthritis deformans
Arthrosis deformans
Nodose rheumatism
Rheumatic arthritis
Rheumatic gout
The following dosing information is available for OLUMIANT (baricitinib):
In patients receiving concomitant therapy with potent inhibitors of organic anion transporter (OAT)3 (e.g., probenecid), reduce the dosage of baricitinib from 4 mg once daily to 2 mg once daily or from 2 mg once daily to 1 mg once daily. If the recommended baricitinib dose is 1 mg once daily, consider discontinuing probenecid.
Baricitinib is administered orally without regard to food. Store baricitinib at 20-25degreesC; excursions permitted between 15-30degreesC.
DRUG LABEL | DOSING TYPE | DOSING INSTRUCTIONS |
---|---|---|
OLUMIANT 2 MG TABLET | Maintenance | Adults take 1 tablet (2 mg) by oral route once daily |
OLUMIANT 4 MG TABLET | Maintenance | Adults take 1 tablet (4 mg) by oral route once daily |
OLUMIANT 1 MG TABLET | Maintenance | Adults take 2 tablets (2 mg) by oral route once daily |
No generic dosing information available.
The following drug interaction information is available for OLUMIANT (baricitinib):
There are 4 contraindications.
These drug combinations generally should not be dispensed or administered to the same patient. A manufacturer label warning that indicates the contraindication warrants inclusion of a drug combination in this category, regardless of clinical evidence or lack of clinical evidence to support the contraindication.
Drug Interaction | Drug Names |
---|---|
Efalizumab; Natalizumab/Immunosuppressives; Immunomodulators SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient. MECHANISM OF ACTION: Natalizumab,(1-3) efalizumab,(4) immunosuppressives, and immunomodulators all suppress the immune system. CLINICAL EFFECTS: Concurrent use of natalizumab(1-3) or efalizumab(4) with immunosuppressives or immunomodulators may result in an increased risk of infections, including progressive multifocal leukoencephalopathy (PML), an opportunistic infection caused by the JC virus (JCV). PREDISPOSING FACTORS: Previous JCV infection, longer duration of natalizumab treatment - especially if greater than 2 years, and prior or concomitant treatment with immunosuppressant medication are all independent risk factors which increase the risk for PML.(1,5) The FDA has estimated PML incidence stratified by risk factors: If anti-JCV antibody positive, no prior immunosuppressant use and natalizumab treatment less than 25 months, incidence <1/1,000. If anti-JCV antibody positive, history of prior immunosuppressant use and natalizumab treatment less than 25 months, incidence 2/1,000 If anti-JCV antibody positive, no prior immunosuppressant use and natalizumab treatment 25-48 months, incidence 4/1,000 If anti-JCV antibody positive, history of prior immunosuppressant use and natalizumab treatment 25-48 months, incidence 11/1,000. PATIENT MANAGEMENT: The US manufacturer of natalizumab states patients with Crohn's disease should not receive concurrent immunosuppressants, with the exception of limited overlap of corticosteroids, due to the increased risk for PML. For new natalizumab patients currently receiving chronic oral corticosteroids for Crohn's Disease, begin corticosteroid taper when therapeutic response to natalizumab has occurred. If corticosteroids cannot be discontinued within six months of starting natalizumab, discontinue natalizumab.(3) The US manufacturer of natalizumab states that natalizumab should not ordinarily be used in multiple sclerosis patients receiving immunosuppressants or immunomodulators due to the increased risk for PML. Immunosuppressives include, but are not limited to azathioprine, cyclophosphamide, cyclosporine, mercaptopurine, methotrexate, mitoxantrone, mycophenolate, and corticosteroids.(3,6) The UK manufacturer of natalizumab states that concurrent use with immunosuppressives or antineoplastic agents is contraindicated.(1) The Canadian manufacturer of natalizumab states that natalizumab should not be used with immunosuppressive or immunomodulatory agents.(2) The US manufacturer of certolizumab states that concurrent therapy with natalizumab is not recommended.(7) DISCUSSION: Progressive multifocal leukoencephalopathy has been reported in patients receiving concurrent natalizumab were recently or concomitantly taking immunomodulators or immunosuppressants.(1-5,8,9) In a retrospective cohort study of multiple sclerosis patients newly initiated on a disease-modifying therapy, use of high-efficacy agents (alemtuzumab, natalizumab, or ocrelizumab) resulted in the same risk of overall infections as moderate-efficacy agents, but there was an elevated risk of serious infections (adjusted hazard ratio [aHR] = 1.24, 95% confidence interval (CI) = 1.06-1.44) and UTIs (aHR = 1.21, 95% CI = 1.14-1.30).(10) |
TYSABRI |
Live Vaccines; Live BCG/Selected Immunosuppressive Agents SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient. MECHANISM OF ACTION: A variety of disease modifying agents suppress the immune system. Immunocompromised patients may be at increased risk for uninhibited replication after administration of live, attenuated vaccines or intravesicular BCG. Immune response to vaccines may be decreased during periods of immunocompromise.(1) CLINICAL EFFECTS: The expected serum antibody response may not be obtained and/or the vaccine may result in illness.(1) After instillation of intravesicular BCG, immunosuppression may interfere with local immune response, or increase the severity of mycobacterial infection following inadvertent systemic exposure.(2) PREDISPOSING FACTORS: Immunosuppressive diseases (e.g. hematologic malignancies, HIV disease), treatments (e.g. radiation) and drugs may all increase the magnitude of immunodeficiency. PATIENT MANAGEMENT: The Centers for Disease Control(CDC) Advisory Committee on Immunization Practices (ACIP) states that live-virus and live, attenuated vaccines should not be administered to patients who are immunocompromised. The magnitude of immunocompromise and associated risks should be determined by a physician.(1) For patients scheduled to receive chemotherapy, vaccination should ideally precede the initiation of chemotherapy by 14 days. Patients vaccinated while on immunosuppressive therapy or in the 2 weeks prior to starting therapy should be considered unimmunized and should be revaccinated at least 3 months after discontinuation of therapy.(1) Patients who receive anti-B cell therapies should not receive live vaccines for at least 6 months after such therapies due to a prolonged duration of immunosuppression. An exception is the Zoster vaccine, which can be given at least 1 month after receipt of anti-B cell therapies.(1) The US manufacturer of abatacept states live vaccines should not be given during or for up to 3 months after discontinuation of abatacept.(2) The US manufacturer of live BCG for intravesicular treatment of bladder cancer states use is contraindicated in immunosuppressed patients.(3) The US manufacturer of daclizumab states live vaccines are not recommended during and for up to 4 months after discontinuation of treatment.(4) The US manufacturer of guselkumab states that live vaccines should be avoided during treatment with guselkumab.(5) The US manufacturer of inebilizumab-cdon states that live vaccines are not recommended during treatment and after discontinuation until B-cell repletion. Administer all live vaccinations at least 4 weeks prior to initiation of inebilizumab-cdon.(6) The US manufacturer of ocrelizumab states that live vaccines are not recommended during treatment and until B-cell repletion occurs after discontinuation of therapy. Administer all live vaccines at least 4 weeks prior to initiation of ocrelizumab.(7) The US manufacturer of ozanimod states that live vaccines should be avoided during and for up to 3 months after discontinuation of ozanimod.(8) The US manufacturer of siponimod states that live vaccines are not recommended during treatment and for up to 4 weeks after discontinuation of treatment.(9) The US manufacturer of ustekinumab states BCG vaccines should not be given in the year prior to, during, or the year after ustekinumab therapy.(10) The US manufacturer of satralizumab-mwge states that live vaccines are not recommended during treatment and should be administered at least four weeks prior to initiation of satralizumab-mwge.(11) The US manufacturer of ublituximab-xiiy states that live vaccines are not recommended during treatment and until B-cell recovery. Live vaccines should be administered at least 4 weeks prior to initiation of ublituximab-xiiy.(12) The US manufacturer of etrasimod states that live vaccines should be avoided during and for 5 weeks after treatment. Live vaccines should be administered at least 4 weeks prior to initiation of etrasimod.(13) The US manufacturer of emapalumab-lzsg states that live vaccines should not be administered to patients receiving emapalumab-lzsg and for at least 4 weeks after the last dose of emapalumab-lzsg. The safety of immunization with live vaccines during or following emapalumab-lzsg therapy has not been studied.(14) DISCUSSION: Killed or inactivated vaccines do not pose a danger to immunocompromised patients.(1) Patients with a history of leukemia who are in remission and have not received chemotherapy for at least 3 months are not considered to be immunocompromised.(1) |
ACAM2000 (NATIONAL STOCKPILE), ADENOVIRUS TYPE 4, ADENOVIRUS TYPE 4 AND TYPE 7, ADENOVIRUS TYPE 7, BCG (TICE STRAIN), BCG VACCINE (TICE STRAIN), DENGVAXIA, ERVEBO (NATIONAL STOCKPILE), FLUMIST TRIVALENT 2024-2025, IXCHIQ, M-M-R II VACCINE, PRIORIX, PROQUAD, ROTARIX, ROTATEQ, STAMARIL, VARIVAX VACCINE, VAXCHORA ACTIVE COMPONENT, VAXCHORA VACCINE, VIVOTIF, YF-VAX |
Talimogene laherparepvec/Selected Immunosuppressants SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient. MECHANISM OF ACTION: Talimogene laherparepvec is a live, attenuated herpes simplex virus.(1) CLINICAL EFFECTS: Concurrent use of talimogene laherparepvec in patients receiving immunosuppressive therapy may cause a life-threatening disseminated herpetic infection.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Talimogene laherparepvec is contraindicated in immunosuppressed patients.(1) The magnitude of immunocompromise and associated risks due to immunosuppressant drugs should be determined by a physician. DISCUSSION: Concurrent use of talimogene laherparepvec in patients receiving immunosuppressive therapy may cause a life-threatening disseminated herpetic infection.(1) |
IMLYGIC |
Nadofaragene Firadenovec/Selected Immunosuppressants SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient. MECHANISM OF ACTION: Nadofaragene firadenovec may contain low levels of replication-competent adenovirus.(1) CLINICAL EFFECTS: Concurrent use of nadofaragene firadenovec in patients receiving immunosuppressive therapy may cause disseminated adenovirus infection.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: Individuals who are immunosuppressed or immune-deficient should not receive nadofaragene firadenovec.(1) DISCUSSION: Nadofaragene firadenovec is a non-replicating adenoviral vector-based gene therapy but may contain low levels of replication-competent adenovirus. Immunocompromised persons, including those receiving immunosuppressant therapy, may be at risk for disseminated adenovirus infection.(1) |
ADSTILADRIN |
There are 9 severe interactions.
These drug interactions can produce serious consequences in most patients. Actions required for severe interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration scheduling, and providing additional patient monitoring. Review the full interaction monograph for more information.
Drug Interaction | Drug Names |
---|---|
Baricitinib/OAT3 Inhibitors SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Inhibitors of organic anion transporter 3 (OAT3) may inhibit the renal elimination of baricitinib.(1,2) CLINICAL EFFECTS: Concurrent use of organic anion transporter 3 (OAT3) inhibitors may result in an increase in both the therapeutic and toxic effects of baricitinib.(1,2) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: If concurrent therapy with a strong organic anion transporter 3 (OAT3) inhibitor is warranted, and the recommended dosage is 4 mg once daily, reduce to 2 mg once daily. If the recommended dosage is 2 mg once daily, reduce dose to 1 mg once daily. If the recommended dosage is 1 mg once daily, consider discontinuing probenecid.(2) OAT3 inhibitors with less inhibitor potency are not expected to cause a clinically significant change in baricitinib levels.(1,2) DISCUSSION: In a clinical pharmacology study, dosing of probenecid (an OAT3 inhibitor with strong inhibition potential) resulted in approximately a 2-fold increase in area-under-curve (AUC) with no change in time maximum (Tmax) or concentration maximum (Cmax) of baricitinib.(1,2) OAT3 inhibitors linked to this monograph include: probenecid and vadadustat.(1-3) |
PROBENECID, PROBENECID-COLCHICINE, VAFSEO |
Baricitinib/Immunosuppressives; Immunomodulators SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Concurrent use of baricitinib with other biologic disease-modifying antirheumatic drugs (DMARDs) or potent immunosuppressants such as azathioprine or cyclosporine may result in additive or synergistic effects on the immune system. CLINICAL EFFECTS: Concurrent use of baricitinib with other biologic DMARDs or potent immunosuppressants such as azathioprine or cyclosporine may increase the risk of serious infections.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: The US manufacturer of baricitinib states that concurrent use of baricitinib with biologic DMARDs or potent immunosuppressants is not recommended.(1) DISCUSSION: Most patients who developed serious infections while being treated with baricitinib were on concomitant immunosuppressants like methotrexate and corticosteroids. The combination of baricitinib with other biologic DMARDs has not been studied.(1) |
ABECMA, ABRAXANE, ABRILADA(CF), ABRILADA(CF) PEN, ABRILADA(CF) PEN (2 PACK), ACTEMRA, ACTEMRA ACTPEN, ACTIMMUNE, ADALIMUMAB-AACF(CF), ADALIMUMAB-AACF(CF) (2 PK), ADALIMUMAB-AACF(CF) PEN (2 PK), ADALIMUMAB-AACF(CF) PEN CROHNS, ADALIMUMAB-AACF(CF) PEN PS-UV, ADALIMUMAB-AATY(CF) (2 PACK), ADALIMUMAB-AATY(CF) (2 PK), ADALIMUMAB-AATY(CF) AUTOINJ(2), ADALIMUMAB-AATY(CF) AUTOINJECT, ADALIMUMAB-ADAZ(CF), ADALIMUMAB-ADAZ(CF) PEN, ADALIMUMAB-ADBM(CF), ADALIMUMAB-ADBM(CF) PEN, ADALIMUMAB-ADBM(CF) PEN CROHNS, ADALIMUMAB-ADBM(CF) PEN PS-UV, ADALIMUMAB-ADBM(CF)PEN, ADALIMUMAB-FKJP(CF), ADALIMUMAB-FKJP(CF) PEN, ADALIMUMAB-RYVK(CF), ADALIMUMAB-RYVK(CF) AUTOINJECT, ADCETRIS, ADRIAMYCIN, ADRUCIL, AFINITOR, AFINITOR DISPERZ, AGAMREE, AKEEGA, ALFERON N, ALIMTA, ALIQOPA, ALKERAN, ALKINDI SPRINKLE, ALUNBRIG, ALYMSYS, AMJEVITA(CF), AMJEVITA(CF) AUTOINJECTOR, AMTAGVI, ANUCORT-HC, ANUSOL-HC, ARCALYST, ARRANON, ARSENIC TRIOXIDE, ARZERRA, ASPARLAS, ASTAGRAF XL, AUCATZYL, AUGTYRO, AVASTIN, AVONEX, AVONEX (4 PACK), AVONEX PEN, AVONEX PEN (4 PACK), AVSOLA, AXTLE, AZACITIDINE, AZASAN, AZATHIOPRINE, AZATHIOPRINE SODIUM, AZELAIC ACID, BAFIERTAM, BAVENCIO, BECLOMETHASONE DIPROPIONATE, BELEODAQ, BELRAPZO, BENDAMUSTINE HCL, BENDEKA, BESPONSA, BESREMI, BETA 1, BETALOAN SUIK, BETAMETHASONE ACETATE MICRO, BETAMETHASONE ACETATE-SOD PHOS, BETAMETHASONE DIPROPIONATE, BETAMETHASONE SOD PHOS-ACETATE, BETAMETHASONE SOD PHOS-WATER, BETAMETHASONE SODIUM PHOSPHATE, BETAMETHASONE VALERATE, BETASERON, BEXAROTENE, BICNU, BIMZELX, BIMZELX AUTOINJECTOR, BLEOMYCIN SULFATE, BLINCYTO, BORTEZOMIB, BORUZU, BOSULIF, BRAFTOVI, BREYANZI, BREYANZI CD4 COMPONENT, BREYANZI CD8 COMPONENT, BRIUMVI, BRUKINSA, BSP 0820, BUDESONIDE, BUDESONIDE DR, BUDESONIDE EC, BUDESONIDE ER, BUDESONIDE MICRONIZED, BUSULFAN, BUSULFEX, CAELYX, CALQUENCE, CAMPATH, CAMPTOSAR, CAPECITABINE, CARBOPLATIN, CARMUSTINE, CARVYKTI, CELESTONE, CELLCEPT, CIBINQO, CIMZIA, CIMZIA (2 PACK), CISPLATIN, CLADRIBINE, CLOBETASOL PROPIONATE MICRO, CLOFARABINE, COLUMVI, COPAXONE, COPIKTRA, CORTEF, CORTENEMA, CORTIFOAM, CORTISONE ACETATE, COSENTYX, COSENTYX (2 SYRINGES), COSENTYX SENSOREADY (2 PENS), COSENTYX SENSOREADY PEN, COSENTYX SYRINGE, COSENTYX UNOREADY PEN, COSMEGEN, CYCLOPHOSPHAMIDE, CYCLOSPORINE, CYCLOSPORINE MODIFIED, CYLTEZO(CF), CYLTEZO(CF) PEN, CYLTEZO(CF) PEN CROHN'S-UC-HS, CYLTEZO(CF) PEN PSORIASIS-UV, CYTARABINE, DACARBAZINE, DACOGEN, DACTINOMYCIN, DANYELZA, DANZITEN, DARAPRIM, DARZALEX, DARZALEX FASPRO, DASATINIB, DAUNORUBICIN HCL, DAURISMO, DECITABINE, DEFLAZACORT, DEPO-MEDROL, DESONIDE MICRONIZED, DESOXIMETASONE, DEXABLISS, DEXAMETHASONE, DEXAMETHASONE ACETATE, DEXAMETHASONE ACETATE MICRO, DEXAMETHASONE INTENSOL, DEXAMETHASONE ISONICOTINATE, DEXAMETHASONE MICRONIZED, DEXAMETHASONE SOD PHOS-WATER, DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE-0.9% NACL, DEXRAZOXANE, DIMETHYL FUMARATE, DMT SUIK, DOCETAXEL, DOCIVYX, DOUBLEDEX, DOXIL, DOXORUBICIN HCL, DOXORUBICIN HCL LIPOSOME, DROXIA, EFLORNITHINE HCL, ELAHERE, ELLENCE, ELREXFIO, EMFLAZA, ENBREL, ENBREL MINI, ENBREL SURECLICK, ENHERTU, ENSPRYNG, ENTYVIO, ENTYVIO PEN, ENVARSUS XR, EOHILIA, EPIRUBICIN HCL, EPKINLY, ERBITUX, ERLOTINIB HCL, ERWINASE, ETOPOPHOS, ETOPOSIDE, EVEROLIMUS, EVOMELA, FARYDAK, FLOXURIDINE, FLUDARABINE PHOSPHATE, FLUNISOLIDE, FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE MICRO, FLUOCINONIDE MICRONIZED, FLUOROURACIL, FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE MICRO, FOLOTYN, FRINDOVYX, FYARRO, GAMIFANT, GAVRETO, GAZYVA, GEFITINIB, GEMCITABINE HCL, GENGRAF, GLATIRAMER ACETATE, GLATOPA, GLEEVEC, GLEOSTINE, GLIADEL, GRAFAPEX, HADLIMA, HADLIMA PUSHTOUCH, HADLIMA(CF), HADLIMA(CF) PUSHTOUCH, HEMADY, HEMMOREX-HC, HEPZATO, HERCEPTIN, HERCEPTIN HYLECTA, HERCESSI, HERZUMA, HEXATRIONE, HULIO(CF), HULIO(CF) PEN, HUMIRA, HUMIRA PEN, HUMIRA(CF), HUMIRA(CF) PEN, HUMIRA(CF) PEN CROHN'S-UC-HS, HUMIRA(CF) PEN PSOR-UV-ADOL HS, HYCAMTIN, HYDREA, HYDROCORTISONE, HYDROCORTISONE ACETATE, HYDROCORTISONE SOD SUCCINATE, HYDROCORTISONE-PRAMOXINE, HYDROXYUREA, HYRIMOZ, HYRIMOZ PEN, HYRIMOZ(CF), HYRIMOZ(CF) PEDIATRIC CROHN'S, HYRIMOZ(CF) PEN, HYRIMOZ(CF) PEN CROHN-UC START, HYRIMOZ(CF) PEN PSORIASIS, IBRANCE, ICLUSIG, IDAMYCIN PFS, IDARUBICIN HCL, IFEX, IFOSFAMIDE, ILARIS, IMATINIB MESYLATE, IMBRUVICA, IMDELLTRA, IMFINZI, IMKELDI, IMURAN, INFLECTRA, INFLIXIMAB, INFUGEM, INQOVI, INREBIC, IRESSA, IRINOTECAN HCL, ISTODAX, IVRA, IWILFIN, IXEMPRA, JAYPIRCA, JEMPERLI, JEVTANA, JOENJA, JYLAMVO, KADCYLA, KANJINTI, KEMOPLAT, KENALOG-10, KENALOG-40, KENALOG-80, KESIMPTA PEN, KEVZARA, KEYTRUDA, KINERET, KISQALI, KYMRIAH, LAPATINIB, LEMTRADA, LENALIDOMIDE, LEUKERAN, LIDOCIDEX-I, LITFULO, LONSURF, LOQTORZI, LUNSUMIO, LUTATHERA, LYNPARZA, MAS CARE-PAK, MATULANE, MAVENCLAD, MEDROL, MEDROLOAN II SUIK, MEDROLOAN SUIK, MEKINIST, MEKTOVI, MELPHALAN HCL, MERCAPTOPURINE, METHOTREXATE, METHOTREXATE SODIUM, METHYLPREDNISOLONE, METHYLPREDNISOLONE AC MICRO, METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE SODIUM SUCC, MILLIPRED, MILLIPRED DP, MITOMYCIN, MITOXANTRONE HCL, MOMETASONE FUROATE, MONJUVI, MUTAMYCIN, MVASI, MYCOPHENOLATE MOFETIL, MYCOPHENOLIC ACID, MYFORTIC, MYHIBBIN, MYLERAN, NELARABINE, NEORAL, NIPENT, NULOJIX, OCREVUS, OCREVUS ZUNOVO, OGIVRI, OJJAARA, ONCASPAR, ONIVYDE, ONTRUZANT, ONUREG, OPDIVO, OPDIVO QVANTIG, OPDUALAG, ORAPRED ODT, ORENCIA, ORENCIA CLICKJECT, ORTIKOS, OTREXUP, OXALIPLATIN, PACLITAXEL, PACLITAXEL PROTEIN-BOUND, PADCEV, PARAPLATIN, PAZOPANIB HCL, PEDIAPRED, PEGASYS, PEMETREXED, PEMETREXED DISODIUM, PEMFEXY, PEMRYDI RTU, PERJETA, PHESGO, PHOTOFRIN, PLEGRIDY, PLEGRIDY PEN, PLUVICTO, POLIVY, POMALYST, POTELIGEO, PRALATREXATE, PREDNISOLONE, PREDNISOLONE ACETATE MICRONIZE, PREDNISOLONE MICRONIZED, PREDNISOLONE SODIUM PHOS ODT, PREDNISOLONE SODIUM PHOSPHATE, PREDNISONE, PREDNISONE INTENSOL, PREDNISONE MICRONIZED, PRO-C-DURE 5, PRO-C-DURE 6, PROCARBAZINE HCL, PROCTOCORT, PROGRAF, PROLEUKIN, PROVENGE, PURIXAN, PYRIMETHAMINE, QUALAQUIN, QUININE HCL, QUININE SULFATE, RASUVO, RAYOS, REBIF, REBIF REBIDOSE, REMICADE, RENFLEXIS, REVLIMID, REVUFORJ, REZUROCK, RIABNI, RITUXAN, RITUXAN HYCELA, ROMIDEPSIN, RUBRACA, RUXIENCE, RYDAPT, RYLAZE, RYTELO, SANDIMMUNE, SARCLISA, SCEMBLIX, SIKLOS, SIMLANDI(CF), SIMLANDI(CF) AUTOINJECTOR, SIMPONI, SIMPONI ARIA, SIMULECT, SIROLIMUS, SODIUM IODIDE I-123, SOLU-CORTEF, SOLU-MEDROL, SOTYKTU, SPRYCEL, STRONTIUM-89 CHLORIDE, SUNITINIB MALATE, SUTENT, TABLOID, TACROLIMUS, TACROLIMUS XL, TALTZ AUTOINJECTOR, TALTZ AUTOINJECTOR (2 PACK), TALTZ AUTOINJECTOR (3 PACK), TALTZ SYRINGE, TALVEY, TALZENNA, TAPERDEX, TARCEVA, TARGRETIN, TARPEYO, TASIGNA, TECARTUS, TECELRA, TECENTRIQ, TECENTRIQ HYBREZA, TECFIDERA, TECVAYLI, TEMODAR, TEMOZOLOMIDE, TEMSIROLIMUS, TEPADINA, TEVIMBRA, THIOTEPA, TOFIDENCE, TOPOTECAN HCL, TORISEL, TORPENZ, TRAMETINIB, TRAZIMERA, TREANDA, TRETINOIN, TREXALL, TRIAMCINOLONE, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE DIACETATE, TRIAMCINOLONE DIACETATE MICRO, TRILOAN II SUIK, TRILOAN SUIK, TRISENOX, TRODELVY, TRUQAP, TRUXIMA, TYENNE, TYENNE AUTOINJECTOR, TYKERB, TZIELD, UCERIS, UNITUXIN, UPLIZNA, UVADEX, VANFLYTA, VECTIBIX, VEGZELMA, VELCADE, VENCLEXTA, VENCLEXTA STARTING PACK, VERIPRED 20, VERZENIO, VIDAZA, VINBLASTINE SULFATE, VINCASAR PFS, VINCRISTINE SULFATE, VINORELBINE TARTRATE, VITRAKVI, VIVIMUSTA, VOTRIENT, VUMERITY, XALKORI, XATMEP, XELODA, XOFIGO, XPOVIO, XROMI, YESCARTA, YONDELIS, YUFLYMA(CF) (2 PACK), YUFLYMA(CF) AI CROHN'S-UC-HS, YUFLYMA(CF) AUTOINJECT (2 PCK), YUFLYMA(CF) AUTOINJECTOR, YUSIMRY(CF) PEN, ZCORT, ZEJULA, ZEPZELCA, ZEVALIN, ZILRETTA, ZIRABEV, ZOKINVY, ZOLINZA, ZORTRESS, ZYDELIG, ZYMFENTRA, ZYMFENTRA (2 PACK), ZYMFENTRA PEN (2 PACK), ZYNLONTA, ZYNYZ |
Ponesimod/Immunosuppressives; Immunomodulators SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Ponesimod in combination with immunosuppressives and immune-modulators all suppress the immune system.(1) CLINICAL EFFECTS: Concurrent use of ponesimod with immunosuppressive or immune-modulating agents may result in an increased risk of serious infections, such as disseminated herpetic infection, cryptococcal infection, or progressive multifocal leukoencephalopathy (PML), an opportunistic infection caused by the JC virus (JCV).(1) PREDISPOSING FACTORS: Incomplete washout of previously prescribed immunosuppressive or immune-modulating medications. PATIENT MANAGEMENT: The ponesimod US prescribing information states ponesimod has not been studied in combination with anti-neoplastic, immune-modulating, or immunosuppressive therapies. Caution should be used during concomitant administration because of the risk of additive immune effects during therapy and in the weeks following administration. When switching from drugs with prolonged immune effects, the half-life and mode of action of these drugs must be considered in order to avoid unintended additive immunosuppressive effects. Initiating treatment with ponesimod after alemtuzumab is not recommended. However, ponesimod can generally be started immediately after discontinuation of beta interferon or glatiramer acetate.(1) DISCUSSION: Fatal disseminated herpes zoster and herpes simplex infections, cryptococcal meningitis, disseminated cryptococcal infections, and cases of progressive multifocal leukoencephalopathy (PML) have been reported in patients who previously received immunomodulators or immunosuppressants.(1) |
PONVORY |
Sodium Iodide I 131/Myelosuppressives; Immunomodulators SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Sodium iodide I 131 can cause depression of the hematopoetic system. Myelosuppressives and immunomodulators also suppress the immune system.(1) CLINICAL EFFECTS: Concurrent use of sodium iodide I 131 with agents that cause bone marrow depression, including myelosuppressives or immunomodulators, may result in an enhanced risk of hematologic disorders, including anemia, blood dyscrasias, bone marrow depression, leukopenia, and thrombocytopenia. Bone marrow depression may increase the risk of serious infections and bleeding.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: The US manufacturer of sodium iodide I 131 states that concurrent use with bone marrow depressants may enhance the depression of the hematopoetic system caused by large doses of sodium iodide I 131.(1) Sodium iodide I 131 causes a dose-dependent bone marrow suppression, including neutropenia or thrombocytopenia, in the 3 to 5 weeks following administration. Patients may be at increased risk of infections or bleeding during this time. Monitor complete blood counts within one month of therapy. If results indicate leukopenia or thrombocytopenia, dosimetry should be used to determine a safe sodium iodide I 131 activity.(1) DISCUSSION: Hematologic disorders including death have been reported with sodium iodide I 131. The most common hematologic disorders reported include anemia, blood dyscrasias, bone marrow depression, leukopenia, and thrombocytopenia.(1) |
HICON, SODIUM IODIDE I-131 |
Fingolimod/Immunosuppressives; Immunomodulators SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Fingolimod in combination with immunosuppressives and immune-modulators all suppress the immune system.(1-3) CLINICAL EFFECTS: Concurrent use of fingolimod with immunosuppressive or immune-modulating agents may result in an increased risk of serious infections, such as disseminated herpetic infection or progressive multifocal leukoencephalopathy (PML), an opportunistic infection caused by the JC virus (JCV).(1-3) PREDISPOSING FACTORS: Incomplete washout of previously prescribed immunosuppressive or immune-modulating medications. PATIENT MANAGEMENT: Recommendations for fingolimod regarding this interaction differ between regulatory approving agencies. The fingolimod US prescribing information states: - Antineoplastic, immune-modulating, or immunosuppressive therapies, (including corticosteroids) are expected to increase the risk of immunosuppression, and the risk of additive immune system effects must be considered if these therapies are coadministered with fingolimod. When switching from drugs with prolonged immune effects, such as natalizumab, teriflunomide or mitoxantrone, the duration and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects when initiating fingolimod.(1) The fingolimod Canadian prescribing information states: - Concurrent use with immunosuppressive or immunomodulatory agents is contraindicated due to the risk of additive immune system effects. However, co-administration of a short course of corticosteroids (up to 5 days) did not increase the overall rate of infection in patients participating Phase III clinical trials.(2) The fingolimod UK specific product characteristics states: - Fingolimod is contraindicated in patients currently receiving immunosuppressive therapies or those immunocompromised by prior therapies. When switching patients from another disease modifying therapy to Gilenya, the half-life and mode of action of the other therapy must be considered in order to avoid an additive immune effect whilst at the same time minimizing the risk of disease activation.(3) DISCUSSION: Fatal disseminated herpes zoster and herpes simplex infections and cases of progressive multifocal leukoencephalopathy (PML) have been reported in patients who previously received immunomodulators or immunosuppressants.(1-3) |
FINGOLIMOD, GILENYA, TASCENSO ODT |
Ozanimod/Immunosuppressives; Immunomodulators SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Ozanimod in combination with immunosuppressives and immune-modulators all suppress the immune system.(1) CLINICAL EFFECTS: Concurrent use of ozanimod with immunosuppressive or immune-modulating agents may result in an increased risk of serious infections, such as disseminated herpetic infection or progressive multifocal leukoencephalopathy (PML), an opportunistic infection caused by the JC virus (JCV).(1) PREDISPOSING FACTORS: Incomplete washout of previously prescribed immunosuppressive or immune-modulating medications. PATIENT MANAGEMENT: The ozanimod US prescribing information state this information regarding this interaction: -Ozanimod has not been studied in combination with anti-neoplastic, immune-modulating, or immunosuppressive therapies. Caution should be used during concomitant administration because of the risk of additive immune effects during therapy and in the week following administration. When switching from drugs with prolonged immune effects, the half-life and mode of action of these drugs must be considered in order to avoid unintended additive immunosuppressive effects. Initiating treatment with ozanimod after alemtuzumab is not recommended. However, ozanimod can generally be started immediately after discontinuation of beta interferon or glatiramer acetate.(1) DISCUSSION: Fatal disseminated herpes zoster and herpes simplex infections and cases of progressive multifocal leukoencephalopathy (PML) have been reported in patients who previously received immunomodulators or immunosuppressants.(1) |
ZEPOSIA |
Siponimod/Immunosuppressives; Immunomodulators SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Siponimod in combination with immunosuppressives and immune-modulators all suppress the immune system.(1) CLINICAL EFFECTS: Concurrent use of siponimod with immunosuppressive or immune-modulating agents may result in an increased risk of serious infections, such as disseminated herpetic infection or progressive multifocal leukoencephalopathy (PML), an opportunistic infection caused by the JC virus (JCV).(1) PREDISPOSING FACTORS: Incomplete washout of previously prescribed immunosuppressive or immune-modulating medications. PATIENT MANAGEMENT: The siponimod US prescribing information state this information regarding this interaction: -Siponimod has not been studied in combination with anti-neoplastic, immune-modulating, or immunosuppressive therapies. Caution should be used during concomitant administration because of the risk of additive immune effects during therapy and in the week following administration. When switching from drugs with prolonged immune effects, the half-life and mode of action of these drugs must be considered in order to avoid unintended additive immunosuppressive effects. Initiating treatment with siponimod after alemtuzumab is not recommended. However, siponimod can generally be started immediately after discontinuation of beta interferon or glatiramer acetate.(1) DISCUSSION: Fatal disseminated herpes zoster and herpes simplex infections and cases of progressive multifocal leukoencephalopathy (PML) have been reported in patients who previously received immunomodulators or immunosuppressants.(1) |
MAYZENT |
Etrasimod/Immunosuppressives; Immunomodulators SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Etrasimod causes reversible sequestration of lymphocytes in lymphoid tissues, resulting in a mean 55% decrease in peripheral blood lymphocyte count at 52 weeks.(1) Other immunosuppressives and immune-modulators also suppress the immune system. CLINICAL EFFECTS: Concurrent use of etrasimod with immunosuppressive or immune-modulating agents may result in an increased risk of serious and fatal infections, such as disseminated herpetic infection, cryptococcal infection, or progressive multifocal leukoencephalopathy (PML).(1) PREDISPOSING FACTORS: Incomplete washout of previously prescribed immunosuppressive or immune-modulating medications increases the risk of adverse effects. PATIENT MANAGEMENT: The etrasimod US prescribing information states etrasimod has not been studied in combination with anti-neoplastic, immune-modulating, or immunosuppressive therapies. Concomitant administration of these therapies with etrasimod should be avoided because of the risk of additive immune effects during therapy and in the weeks following administration. Etrasimod's effect on peripheral lymphocytes may persist for up to 5 weeks after discontinuation.(1) When switching from drugs with prolonged immune effects, the half-life and mode of action of these drugs must be considered in order to avoid unintended additive immunosuppressive effects.(1) DISCUSSION: Fatal disseminated herpes zoster and herpes simplex infections, cryptococcal meningitis, disseminated cryptococcal infections, and cases of progressive multifocal leukoencephalopathy (PML) have been reported in patients treated with other sphingosine-1 phosphate receptor modulators.(1) |
VELSIPITY |
Baricitinib/Immunosuppressive OAT3 Inhibitors SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Concurrent use of baricitinib with other potent immunosuppressants may result in additive or synergistic effects on the immune system.(1,2) Inhibitors of organic anion transporter 3 (OAT3) such as leflunomide and teriflunomide(3) may inhibit the renal elimination of baricitinib.(1,2) CLINICAL EFFECTS: Concurrent use of organic anion transporter 3 (OAT3) inhibitors may result in an increase in both the therapeutic and toxic effects of baricitinib and may increase the risk of serious infections.(1,2) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: The US manufacturer of baricitinib states that concurrent use of baricitinib with biologic DMARDs or potent immunosuppressants is not recommended.(1) If concurrent therapy with a strong organic anion transporter 3 (OAT3) inhibitor is warranted, and the recommended dosage is 4 mg once daily, reduce to 2 mg once daily. If the recommended dosage is 2 mg once daily, reduce dose to 1 mg once daily. If the recommended dosage is 1 mg once daily, consider discontinuing probenecid.(2) OAT3 inhibitors with less inhibitor potency are not expected to cause a clinically significant change in baricitinib levels.(1,2) DISCUSSION: In a clinical pharmacology study, dosing of probenecid (an OAT3 inhibitor with strong inhibition potential) resulted in approximately a 2-fold increase in area-under-curve (AUC) with no change in time maximum (Tmax) or concentration maximum (Cmax) of baricitinib.(1,2) Most patients who developed serious infections while being treated with baricitinib were on concomitant immunosuppressants like methotrexate and corticosteroids. The combination of baricitinib with other biologic DMARDs has not been studied.(1) |
ARAVA, AUBAGIO, LEFLUNICLO, LEFLUNOMIDE, TERIFLUNOMIDE |
There are 2 moderate interactions.
The clinician should assess the patient’s characteristics and take action as needed. Actions required for moderate interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration.
Drug Interaction | Drug Names |
---|---|
Ustekinumab/Immunosuppressives; Immunomodulators SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Ustekinumab, immunosuppressives, and immunomodulators all suppress the immune system.(1) CLINICAL EFFECTS: Concurrent use of ustekinumab with immunosuppressive or immunomodulating agents may result in an increased risk for serious infections.(1) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: The US manufacturer of ustekinumab recommends caution because the concurrent use of ustekinumab with immunosuppressive agents may increase the risk of infection. If concurrent therapy is warranted, consider the risk of additive immune suppression and monitor based on prescribing information for both agents.(1) DISCUSSION: Ustekinumab has not been studied in combination with other immunosuppressants in psoriasis studies. In psoriatic arthritis studies, concomitant methotrexate use did not appear to influence the safety or efficacy of ustekinumab. In Crohn's disease and ulcerative colitis studies, concomitant use of immunosuppressants or corticosteroids did not appear to influence the safety or efficacy of ustekinumab. If concurrent therapy is warranted, consider the potential for increased immunosuppressive risks from both agents.(1) The most common infections reported by ustekinumab treated patients in the clinical trial periods included nasopharyngitis(8%) and upper respiratory tract infection(5%). Serious bacterial, mycobacterial, fungal, and viral infections were observed in patients receiving ustekinumab. Cases of interstitial pneumonia, eosinophilic pneumonia, and cryptogenic organizing pneumonia resulting in respiratory failure or prolonged hospitalization have been reported in patients receiving ustekinumab.(1) |
OTULFI, PYZCHIVA, SELARSDI, STELARA, STEQEYMA, USTEKINUMAB-TTWE, WEZLANA, YESINTEK |
COVID-19 Vaccines/Immunosuppressives; Immunomodulators SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: Immunosuppressants and immunomodulators may prevent the immune system from properly responding to the COVID-19 vaccine.(1,2) CLINICAL EFFECTS: Administration of a COVID-19 vaccine with immunosuppressants or immunomodulators may interfere with vaccine-induced immune response and impair the efficacy of the vaccine. However, patients should be offered and given a COVID-19 vaccine even if the use and timing of immunosuppressive agents cannot be adjusted.(1,2) PREDISPOSING FACTORS: None determined. PATIENT MANAGEMENT: In an effort to optimize COVID-19 vaccine response, the American College of Rheumatology (ACR) published conditional recommendations for administration of COVID-19 vaccines with immunosuppressants and immunomodulators.(1) The CDC also provides clinical considerations for COVID-19 vaccination in patients on immunosuppressants.(2) The CDC states that all immunocompromised patients over 6 months of age should receive at least 1 dose of COVID-19 vaccine if eligible. See the CDC's Interim Clinical Considerations for Use of COVID-19 Vaccines for specific recommendations based on age, vaccination history, and vaccine manufacturer.(2) The ACR states that in general, immunosuppressants and immunomodulators should be held for 1-2 weeks after each vaccine dose. See below for specific recommendations for certain agents.(1) The CDC advises planning for vaccination at least 2 weeks before starting or resuming immunosuppressive therapy.(2) Patients should be offered and given a COVID-19 vaccine even if the use and timing of immunosuppressive agents cannot be adjusted.(1,2) B-cell depleting agents, including rituximab: The ACR recommends consulting with the rheumatologist to determine optimal timing of COVID-19 vaccination. Measuring CD19 B cells may be considered to determine need for a booster vaccine dose. If B cell levels are not measured, a supplemental vaccine dose 2-4 weeks before the next scheduled dose of rituximab is recommended.(1) The CDC states that the utility of B-cell quantification to guide clinical care is not known and is not recommended. Patients who receive B-cell depleting therapy should receive COVID-19 vaccines about 4 weeks before the next scheduled dose. For patients who received 1 or more doses of COVID-19 vaccine during treatment with B-cell-depleting therapies that were administered over a limited period (e.g., as part of a treatment regimen for certain malignancies), revaccination may be considered. The suggested interval to start revaccination is about 6 months after completion of the B-cell-depleting therapy.(2) Abatacept: - Subcutaneous abatacept should be withheld for 1-2 weeks after each vaccine dose, as disease activity allows. - For intravenous abatacept, time administration so that vaccination will occur 1 week before the next abatacept infusion.(1) Cyclophosphamide: When feasible, administer cyclophosphamide one week after each COVID-19 vaccine dose.(1) Recipients of hematopoietic cell transplant or CAR-T-cell therapy who received one or more doses of COVID-19 vaccine prior to or during treatment should undergo revaccination following the current CDC recommendations for unvaccinated patients. Revaccination should start at least 3 months (12 weeks) after transplant or CAR-T-cell therapy.(2) TNF-alpha inhibitors and cytokine inhibitors: The ACR was not able to reach consensus on whether to modify dosing or timing of these agents with COVID-19 vaccination.(1) The CDC includes these agents in their general recommendation to hold therapy for at least 2 weeks following vaccination.(2) DISCUSSION: The ACR convened a COVID-19 Vaccine Guidance Task Force to provide guidance on optimal use of COVID-19 vaccines in rheumatology patients. These recommendations are based on limited clinical evidence of COVID-19 vaccines in patients without rheumatic and musculoskeletal disorders and evidence of other vaccines in this patient population.(1) The ACR recommendation for rituximab is based on studies of humoral immunity following receipt of other vaccines. These studies have uncertain generalizability to vaccination against COVID-19, as it is unknown if efficacy is attributable to induction of host T cells versus B cell (antibody-based) immunity.(1) The ACR recommendation for mycophenolate is based on preexisting data of mycophenolate on non-COVID-19 vaccine immunogenicity. Emerging data suggests that mycophenolate may impair SARS-CoV-2 vaccine response in rheumatic and musculoskeletal disease and transplant patients.(1) The ACR recommendation for methotrexate is based on data from influenza vaccines and pneumococcal vaccines with methotrexate.(1) The ACR recommendation for JAK inhibitors is based on concerns related to the effects of JAK inhibitors on interferon signaling that may result in a diminished vaccine response.(1) The ACR recommendation for subcutaneous abatacept is based on several studies suggesting a negative effect of abatacept on vaccine immunogenicity. The first vaccine dose primes naive T cells, naive T cell priming is inhibited by CTLA-4, and abatacept is a CTLA-4Ig construct. CTLA-4 should not inhibit boosts of already primed T cells at the time of the second vaccine dose.(1) |
COMIRNATY 2024-2025, MODERNA COVID 24-25(6M-11Y)EUA, NOVAVAX COVID 2024-2025 (EUA), PFIZER COVID 2024-25(5-11Y)EUA, PFIZER COVID 2024-25(6M-4Y)EUA, SPIKEVAX 2024-2025 |
The following contraindication information is available for OLUMIANT (baricitinib):
Drug contraindication overview.
None.
None.
There are 3 contraindications.
Absolute contraindication.
Contraindication List |
---|
Chronic kidney disease stage 4 (severe) GFR 15-29 ml/min |
Chronic kidney disease stage 5 (failure) GFr<15 ml/min |
Lactation |
There are 15 severe contraindications.
Adequate patient monitoring is recommended for safer drug use.
Severe List |
---|
Active tuberculosis |
Anemia |
Atherosclerotic cardiovascular disease |
Chronic kidney disease stage 3A (moderate) GFR 45-59 ml/min |
Chronic kidney disease stage 3B (moderate) GFR 30-44 ml/min |
Inactive tuberculosis |
Kidney disease with likely reduction in glomerular filtration rate (GFr) |
Lymphopenia |
Malignancy |
Malignant lymphoma |
Neutropenic disorder |
Opportunistic viral infection |
Severe infection |
Thrombotic disorder |
Tobacco smoker |
There are 4 moderate contraindications.
Clinically significant contraindication, where the condition can be managed or treated before the drug may be given safely.
Moderate List |
---|
Disease of liver |
Diverticular disease |
Gastrointestinal perforation |
Hyperlipidemia |
The following adverse reaction information is available for OLUMIANT (baricitinib):
Adverse reaction overview.
Adverse effects occurring in 1% or more of patients receiving baricitinib (2 or 4 mg daily) for the treatment of rheumatoid arthritis include upper respiratory tract infection, nausea, herpes simplex, and herpes zoster. Adverse effects occurring in 1% or more of patients receiving baricitinib for the treatment of COVID-19 in hospitalized adults and in hospitalized pediatric patients+ include increases of liver enzymes, thrombocytosis, creatine phosphokinase increases, neutropenia, deep vein thrombosis, pulmonary embolism, and urinary tract infection. Adverse effects occurring in 1% or more of patients receiving baricitinib for the treatment of alopecia areata include upper respiratory tract infection, headache, acne, hyperlipidemia, blood creatine phosphokinase increase, urinary tract infection, liver enzyme elevations, folliculitis, fatigue, lower respiratory tract infections, nausea, genital Candida infections, anemia, neutropenia, abdominal pain, herpes zoster, and weight increase.
Adverse effects occurring in 1% or more of patients receiving baricitinib (2 or 4 mg daily) for the treatment of rheumatoid arthritis include upper respiratory tract infection, nausea, herpes simplex, and herpes zoster. Adverse effects occurring in 1% or more of patients receiving baricitinib for the treatment of COVID-19 in hospitalized adults and in hospitalized pediatric patients+ include increases of liver enzymes, thrombocytosis, creatine phosphokinase increases, neutropenia, deep vein thrombosis, pulmonary embolism, and urinary tract infection. Adverse effects occurring in 1% or more of patients receiving baricitinib for the treatment of alopecia areata include upper respiratory tract infection, headache, acne, hyperlipidemia, blood creatine phosphokinase increase, urinary tract infection, liver enzyme elevations, folliculitis, fatigue, lower respiratory tract infections, nausea, genital Candida infections, anemia, neutropenia, abdominal pain, herpes zoster, and weight increase.
There are 34 severe adverse reactions.
More Frequent | Less Frequent |
---|---|
None. |
Cellulitis Herpes simplex infection Herpes zoster Increased alanine transaminase Increased aspartate transaminase Thrombotic disorder |
Rare/Very Rare |
---|
Active tuberculosis Acute myocardial infarction Anemia Angioedema Arterial thrombosis Bacterial infection Benign prostatic hyperplasia Cataracts Cystitis Deep venous thrombosis Diverticulitis of gastrointestinal tract Gastrointestinal perforation Hypersensitivity drug reaction Hypertension Infection Influenza Kidney disease with reduction in glomerular filtration rate (GFr) Lymphopenia Malignancy Malignant lymphoma Neutropenic disorder Opportunistic fungal infection Opportunistic viral infection Pneumocystis jirovecii pneumonia Pulmonary thromboembolism Squamous cell carcinoma of skin Thrombocytosis Urticaria |
There are 40 less severe adverse reactions.
More Frequent | Less Frequent |
---|---|
Hyperlipidemia Nausea Upper respiratory infection |
Acne vulgaris Folliculitis Increased creatine kinase level Muscle spasm Urinary tract infection |
Rare/Very Rare |
---|
Arthralgia Back pain Basal cell carcinoma of skin Blurred vision Bronchitis Constipation Cough Depression Diarrhea Dizziness Dyspepsia Erectile dysfunction Esophageal candidiasis Fatigue Fever Gastroenteritis Gastroesophageal reflux disease Headache disorder Insomnia Onychomycosis due to dermatophyte Pain in oropharynx Peripheral edema Pharyngitis Sinusitis Skin inflammation Skin rash Stomatitis Tonsillitis Upper abdominal pain Vomiting Vulvovaginal candidiasis Weight gain |
The following precautions are available for OLUMIANT (baricitinib):
Safety and efficacy of baricitinib have not been established in pediatric patients with rheumatoid arthritis or alopecia areata. The Emergency Use Authorization (EUA) permits use of baricitinib for the treatment of COVID-19 in hospitalized pediatric patients >=2 years old+. Dosing recommendations are based on limited data from ongoing clinical trials evaluating use of baricitinib in pediatric patients with conditions other than COVID-19.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
None |
Severe Precaution
None |
Management or Monitoring Precaution
None |
Based on findings from animal reproduction studies, baricitinib may cause fetal harm during pregnancy. Reduced fetal body weight, dose-related increases in skeletal malformations, and embryolethality (in rabbits only) have been observed in rats and rabbits given baricitinib at dosages producing exposures of 11 and 46 times, respectively, the exposure at the maximum recommended human dosage. However, there was no evidence of developmental toxicity in rats and rabbits at exposure levels approximately 2 and 7 times, respectively, the exposure at the maximum recommended human dosage.
Consider the association between increased disease activity and risk for adverse pregnancy outcomes in women with rheumatoid arthritis. Report pregnancies to the manufacturer according to instructions in the prescribing information.
Consider the association between increased disease activity and risk for adverse pregnancy outcomes in women with rheumatoid arthritis. Report pregnancies to the manufacturer according to instructions in the prescribing information.
It is not known whether baricitinib is distributed into human milk; the drug is distributed into milk in rats. The effects of baricitinib on nursing infants or on milk production are not known. Because of the potential for serious adverse reactions to baricitinib in nursing infants, female patients should be advised not to breast-feed while receiving the drug and for 4 days after the last dose.
In controlled clinical trials of baricitinib in patients with rheumatoid arthritis, 17% of patients were 65 years of age or older, while 2% were 75 years of age and older. No overall differences in safety or efficacy relative to younger adults were observed, but increased sensitivity in some older individuals cannot be ruled out. In controlled trials of baricitinib in patients with alopecia areata, approximately 2% of patients were 65 years of age or older; this number was insufficient to determine whether these patients respond differently from younger patients.
Dosage in geriatric patients should be selected with caution because of possible age-related decreases in renal function. Monitoring of renal function may be useful in such patients.
Dosage in geriatric patients should be selected with caution because of possible age-related decreases in renal function. Monitoring of renal function may be useful in such patients.
The following prioritized warning is available for OLUMIANT (baricitinib):
WARNING: Baricitinib may lower your ability to fight infections. This may make you more likely to get a serious (rarely fatal) infection or make any infection you have worse. The most common serious infections include pneumonia, shingles, and urinary tract infections.
The risk for infections may be higher if you also take other drugs that suppress the immune system (such as methotrexate, corticosteroids). Tell your doctor right away if you have any signs of infection (such as a sore throat that doesn't go away, fever, chills, cough, painful/frequent urination, non-healing skin sores). If treating rheumatoid arthritis or alopecia areata, you should have a tuberculosis (TB) skin test before and during treatment with this medication.
Tell your doctor if you have been near someone with tuberculosis or have lived or traveled in areas where certain fungal infections (such as coccidioidomycosis, histoplasmosis) are common. These areas include the Ohio and Mississippi River valleys and the southwestern United States. Though it is very unlikely to occur, there may be a risk of developing cancer (such as lymphoma, skin cancer, lung cancer) with this medication.
Your risk may be higher if you are a current or past smoker. Tell your doctor right away if you develop symptoms such as fever or cough that doesn't go away, wheezing, unusual lumps/growths, unexplained weight loss, night sweats, change in appearance or size of moles, or unusual skin changes. Baricitinib may rarely cause serious (possibly fatal) problems from blood clots (such as heart attack, stroke, blood clots in the lungs or legs).
You may be at an increased risk for blood clots if you are a current or past smoker, or are 50 years of age or older and have at least one risk factor for heart disease. Discuss the risks and benefits of treatment with your doctor. Get medical help right away if any of these side effects occur: shortness of breath/rapid breathing, chest/jaw/left arm pain, unusual sweating, confusion, sudden dizziness/fainting, pain/swelling/warmth in the groin/calf, sudden/severe headaches, trouble speaking, weakness on one side of the body, or sudden vision changes.
WARNING: Baricitinib may lower your ability to fight infections. This may make you more likely to get a serious (rarely fatal) infection or make any infection you have worse. The most common serious infections include pneumonia, shingles, and urinary tract infections.
The risk for infections may be higher if you also take other drugs that suppress the immune system (such as methotrexate, corticosteroids). Tell your doctor right away if you have any signs of infection (such as a sore throat that doesn't go away, fever, chills, cough, painful/frequent urination, non-healing skin sores). If treating rheumatoid arthritis or alopecia areata, you should have a tuberculosis (TB) skin test before and during treatment with this medication.
Tell your doctor if you have been near someone with tuberculosis or have lived or traveled in areas where certain fungal infections (such as coccidioidomycosis, histoplasmosis) are common. These areas include the Ohio and Mississippi River valleys and the southwestern United States. Though it is very unlikely to occur, there may be a risk of developing cancer (such as lymphoma, skin cancer, lung cancer) with this medication.
Your risk may be higher if you are a current or past smoker. Tell your doctor right away if you develop symptoms such as fever or cough that doesn't go away, wheezing, unusual lumps/growths, unexplained weight loss, night sweats, change in appearance or size of moles, or unusual skin changes. Baricitinib may rarely cause serious (possibly fatal) problems from blood clots (such as heart attack, stroke, blood clots in the lungs or legs).
You may be at an increased risk for blood clots if you are a current or past smoker, or are 50 years of age or older and have at least one risk factor for heart disease. Discuss the risks and benefits of treatment with your doctor. Get medical help right away if any of these side effects occur: shortness of breath/rapid breathing, chest/jaw/left arm pain, unusual sweating, confusion, sudden dizziness/fainting, pain/swelling/warmth in the groin/calf, sudden/severe headaches, trouble speaking, weakness on one side of the body, or sudden vision changes.
The following icd codes are available for OLUMIANT (baricitinib)'s list of indications:
Adjunct tx for COVId-19 requiring oxygen or ventilation | |
J12.82 | Pneumonia due to coronavirus disease 2019 |
U07.1 | COVId-19 |
Alopecia areata | |
L63 | Alopecia areata |
L63.0 | Alopecia (capitis) totalis |
L63.1 | Alopecia universalis |
L63.2 | Ophiasis |
L63.8 | Other alopecia areata |
L63.9 | Alopecia areata, unspecified |
Rheumatoid arthritis | |
M05 | Rheumatoid arthritis with rheumatoid factor |
M05.0 | Felty's syndrome |
M05.00 | Felty's syndrome, unspecified site |
M05.01 | Felty's syndrome, shoulder |
M05.011 | Felty's syndrome, right shoulder |
M05.012 | Felty's syndrome, left shoulder |
M05.019 | Felty's syndrome, unspecified shoulder |
M05.02 | Felty's syndrome, elbow |
M05.021 | Felty's syndrome, right elbow |
M05.022 | Felty's syndrome, left elbow |
M05.029 | Felty's syndrome, unspecified elbow |
M05.03 | Felty's syndrome, wrist |
M05.031 | Felty's syndrome, right wrist |
M05.032 | Felty's syndrome, left wrist |
M05.039 | Felty's syndrome, unspecified wrist |
M05.04 | Felty's syndrome, hand |
M05.041 | Felty's syndrome, right hand |
M05.042 | Felty's syndrome, left hand |
M05.049 | Felty's syndrome, unspecified hand |
M05.05 | Felty's syndrome, hip |
M05.051 | Felty's syndrome, right hip |
M05.052 | Felty's syndrome, left hip |
M05.059 | Felty's syndrome, unspecified hip |
M05.06 | Felty's syndrome, knee |
M05.061 | Felty's syndrome, right knee |
M05.062 | Felty's syndrome, left knee |
M05.069 | Felty's syndrome, unspecified knee |
M05.07 | Felty's syndrome, ankle and foot |
M05.071 | Felty's syndrome, right ankle and foot |
M05.072 | Felty's syndrome, left ankle and foot |
M05.079 | Felty's syndrome, unspecified ankle and foot |
M05.09 | Felty's syndrome, multiple sites |
M05.1 | Rheumatoid lung disease with rheumatoid arthritis |
M05.10 | Rheumatoid lung disease with rheumatoid arthritis of unspecified site |
M05.11 | Rheumatoid lung disease with rheumatoid arthritis of shoulder |
M05.111 | Rheumatoid lung disease with rheumatoid arthritis of right shoulder |
M05.112 | Rheumatoid lung disease with rheumatoid arthritis of left shoulder |
M05.119 | Rheumatoid lung disease with rheumatoid arthritis of unspecified shoulder |
M05.12 | Rheumatoid lung disease with rheumatoid arthritis of elbow |
M05.121 | Rheumatoid lung disease with rheumatoid arthritis of right elbow |
M05.122 | Rheumatoid lung disease with rheumatoid arthritis of left elbow |
M05.129 | Rheumatoid lung disease with rheumatoid arthritis of unspecified elbow |
M05.13 | Rheumatoid lung disease with rheumatoid arthritis of wrist |
M05.131 | Rheumatoid lung disease with rheumatoid arthritis of right wrist |
M05.132 | Rheumatoid lung disease with rheumatoid arthritis of left wrist |
M05.139 | Rheumatoid lung disease with rheumatoid arthritis of unspecified wrist |
M05.14 | Rheumatoid lung disease with rheumatoid arthritis of hand |
M05.141 | Rheumatoid lung disease with rheumatoid arthritis of right hand |
M05.142 | Rheumatoid lung disease with rheumatoid arthritis of left hand |
M05.149 | Rheumatoid lung disease with rheumatoid arthritis of unspecified hand |
M05.15 | Rheumatoid lung disease with rheumatoid arthritis of hip |
M05.151 | Rheumatoid lung disease with rheumatoid arthritis of right hip |
M05.152 | Rheumatoid lung disease with rheumatoid arthritis of left hip |
M05.159 | Rheumatoid lung disease with rheumatoid arthritis of unspecified hip |
M05.16 | Rheumatoid lung disease with rheumatoid arthritis of knee |
M05.161 | Rheumatoid lung disease with rheumatoid arthritis of right knee |
M05.162 | Rheumatoid lung disease with rheumatoid arthritis of left knee |
M05.169 | Rheumatoid lung disease with rheumatoid arthritis of unspecified knee |
M05.17 | Rheumatoid lung disease with rheumatoid arthritis of ankle and foot |
M05.171 | Rheumatoid lung disease with rheumatoid arthritis of right ankle and foot |
M05.172 | Rheumatoid lung disease with rheumatoid arthritis of left ankle and foot |
M05.179 | Rheumatoid lung disease with rheumatoid arthritis of unspecified ankle and foot |
M05.19 | Rheumatoid lung disease with rheumatoid arthritis of multiple sites |
M05.2 | Rheumatoid vasculitis with rheumatoid arthritis |
M05.20 | Rheumatoid vasculitis with rheumatoid arthritis of unspecified site |
M05.21 | Rheumatoid vasculitis with rheumatoid arthritis of shoulder |
M05.211 | Rheumatoid vasculitis with rheumatoid arthritis of right shoulder |
M05.212 | Rheumatoid vasculitis with rheumatoid arthritis of left shoulder |
M05.219 | Rheumatoid vasculitis with rheumatoid arthritis of unspecified shoulder |
M05.22 | Rheumatoid vasculitis with rheumatoid arthritis of elbow |
M05.221 | Rheumatoid vasculitis with rheumatoid arthritis of right elbow |
M05.222 | Rheumatoid vasculitis with rheumatoid arthritis of left elbow |
M05.229 | Rheumatoid vasculitis with rheumatoid arthritis of unspecified elbow |
M05.23 | Rheumatoid vasculitis with rheumatoid arthritis of wrist |
M05.231 | Rheumatoid vasculitis with rheumatoid arthritis of right wrist |
M05.232 | Rheumatoid vasculitis with rheumatoid arthritis of left wrist |
M05.239 | Rheumatoid vasculitis with rheumatoid arthritis of unspecified wrist |
M05.24 | Rheumatoid vasculitis with rheumatoid arthritis of hand |
M05.241 | Rheumatoid vasculitis with rheumatoid arthritis of right hand |
M05.242 | Rheumatoid vasculitis with rheumatoid arthritis of left hand |
M05.249 | Rheumatoid vasculitis with rheumatoid arthritis of unspecified hand |
M05.25 | Rheumatoid vasculitis with rheumatoid arthritis of hip |
M05.251 | Rheumatoid vasculitis with rheumatoid arthritis of right hip |
M05.252 | Rheumatoid vasculitis with rheumatoid arthritis of left hip |
M05.259 | Rheumatoid vasculitis with rheumatoid arthritis of unspecified hip |
M05.26 | Rheumatoid vasculitis with rheumatoid arthritis of knee |
M05.261 | Rheumatoid vasculitis with rheumatoid arthritis of right knee |
M05.262 | Rheumatoid vasculitis with rheumatoid arthritis of left knee |
M05.269 | Rheumatoid vasculitis with rheumatoid arthritis of unspecified knee |
M05.27 | Rheumatoid vasculitis with rheumatoid arthritis of ankle and foot |
M05.271 | Rheumatoid vasculitis with rheumatoid arthritis of right ankle and foot |
M05.272 | Rheumatoid vasculitis with rheumatoid arthritis of left ankle and foot |
M05.279 | Rheumatoid vasculitis with rheumatoid arthritis of unspecified ankle and foot |
M05.29 | Rheumatoid vasculitis with rheumatoid arthritis of multiple sites |
M05.3 | Rheumatoid heart disease with rheumatoid arthritis |
M05.30 | Rheumatoid heart disease with rheumatoid arthritis of unspecified site |
M05.31 | Rheumatoid heart disease with rheumatoid arthritis of shoulder |
M05.311 | Rheumatoid heart disease with rheumatoid arthritis of right shoulder |
M05.312 | Rheumatoid heart disease with rheumatoid arthritis of left shoulder |
M05.319 | Rheumatoid heart disease with rheumatoid arthritis of unspecified shoulder |
M05.32 | Rheumatoid heart disease with rheumatoid arthritis of elbow |
M05.321 | Rheumatoid heart disease with rheumatoid arthritis of right elbow |
M05.322 | Rheumatoid heart disease with rheumatoid arthritis of left elbow |
M05.329 | Rheumatoid heart disease with rheumatoid arthritis of unspecified elbow |
M05.33 | Rheumatoid heart disease with rheumatoid arthritis of wrist |
M05.331 | Rheumatoid heart disease with rheumatoid arthritis of right wrist |
M05.332 | Rheumatoid heart disease with rheumatoid arthritis of left wrist |
M05.339 | Rheumatoid heart disease with rheumatoid arthritis of unspecified wrist |
M05.34 | Rheumatoid heart disease with rheumatoid arthritis of hand |
M05.341 | Rheumatoid heart disease with rheumatoid arthritis of right hand |
M05.342 | Rheumatoid heart disease with rheumatoid arthritis of left hand |
M05.349 | Rheumatoid heart disease with rheumatoid arthritis of unspecified hand |
M05.35 | Rheumatoid heart disease with rheumatoid arthritis of hip |
M05.351 | Rheumatoid heart disease with rheumatoid arthritis of right hip |
M05.352 | Rheumatoid heart disease with rheumatoid arthritis of left hip |
M05.359 | Rheumatoid heart disease with rheumatoid arthritis of unspecified hip |
M05.36 | Rheumatoid heart disease with rheumatoid arthritis of knee |
M05.361 | Rheumatoid heart disease with rheumatoid arthritis of right knee |
M05.362 | Rheumatoid heart disease with rheumatoid arthritis of left knee |
M05.369 | Rheumatoid heart disease with rheumatoid arthritis of unspecified knee |
M05.37 | Rheumatoid heart disease with rheumatoid arthritis of ankle and foot |
M05.371 | Rheumatoid heart disease with rheumatoid arthritis of right ankle and foot |
M05.372 | Rheumatoid heart disease with rheumatoid arthritis of left ankle and foot |
M05.379 | Rheumatoid heart disease with rheumatoid arthritis of unspecified ankle and foot |
M05.39 | Rheumatoid heart disease with rheumatoid arthritis of multiple sites |
M05.4 | Rheumatoid myopathy with rheumatoid arthritis |
M05.40 | Rheumatoid myopathy with rheumatoid arthritis of unspecified site |
M05.41 | Rheumatoid myopathy with rheumatoid arthritis of shoulder |
M05.411 | Rheumatoid myopathy with rheumatoid arthritis of right shoulder |
M05.412 | Rheumatoid myopathy with rheumatoid arthritis of left shoulder |
M05.419 | Rheumatoid myopathy with rheumatoid arthritis of unspecified shoulder |
M05.42 | Rheumatoid myopathy with rheumatoid arthritis of elbow |
M05.421 | Rheumatoid myopathy with rheumatoid arthritis of right elbow |
M05.422 | Rheumatoid myopathy with rheumatoid arthritis of left elbow |
M05.429 | Rheumatoid myopathy with rheumatoid arthritis of unspecified elbow |
M05.43 | Rheumatoid myopathy with rheumatoid arthritis of wrist |
M05.431 | Rheumatoid myopathy with rheumatoid arthritis of right wrist |
M05.432 | Rheumatoid myopathy with rheumatoid arthritis of left wrist |
M05.439 | Rheumatoid myopathy with rheumatoid arthritis of unspecified wrist |
M05.44 | Rheumatoid myopathy with rheumatoid arthritis of hand |
M05.441 | Rheumatoid myopathy with rheumatoid arthritis of right hand |
M05.442 | Rheumatoid myopathy with rheumatoid arthritis of left hand |
M05.449 | Rheumatoid myopathy with rheumatoid arthritis of unspecified hand |
M05.45 | Rheumatoid myopathy with rheumatoid arthritis of hip |
M05.451 | Rheumatoid myopathy with rheumatoid arthritis of right hip |
M05.452 | Rheumatoid myopathy with rheumatoid arthritis of left hip |
M05.459 | Rheumatoid myopathy with rheumatoid arthritis of unspecified hip |
M05.46 | Rheumatoid myopathy with rheumatoid arthritis of knee |
M05.461 | Rheumatoid myopathy with rheumatoid arthritis of right knee |
M05.462 | Rheumatoid myopathy with rheumatoid arthritis of left knee |
M05.469 | Rheumatoid myopathy with rheumatoid arthritis of unspecified knee |
M05.47 | Rheumatoid myopathy with rheumatoid arthritis of ankle and foot |
M05.471 | Rheumatoid myopathy with rheumatoid arthritis of right ankle and foot |
M05.472 | Rheumatoid myopathy with rheumatoid arthritis of left ankle and foot |
M05.479 | Rheumatoid myopathy with rheumatoid arthritis of unspecified ankle and foot |
M05.49 | Rheumatoid myopathy with rheumatoid arthritis of multiple sites |
M05.5 | Rheumatoid polyneuropathy with rheumatoid arthritis |
M05.50 | Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified site |
M05.51 | Rheumatoid polyneuropathy with rheumatoid arthritis of shoulder |
M05.511 | Rheumatoid polyneuropathy with rheumatoid arthritis of right shoulder |
M05.512 | Rheumatoid polyneuropathy with rheumatoid arthritis of left shoulder |
M05.519 | Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified shoulder |
M05.52 | Rheumatoid polyneuropathy with rheumatoid arthritis of elbow |
M05.521 | Rheumatoid polyneuropathy with rheumatoid arthritis of right elbow |
M05.522 | Rheumatoid polyneuropathy with rheumatoid arthritis of left elbow |
M05.529 | Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified elbow |
M05.53 | Rheumatoid polyneuropathy with rheumatoid arthritis of wrist |
M05.531 | Rheumatoid polyneuropathy with rheumatoid arthritis of right wrist |
M05.532 | Rheumatoid polyneuropathy with rheumatoid arthritis of left wrist |
M05.539 | Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified wrist |
M05.54 | Rheumatoid polyneuropathy with rheumatoid arthritis of hand |
M05.541 | Rheumatoid polyneuropathy with rheumatoid arthritis of right hand |
M05.542 | Rheumatoid polyneuropathy with rheumatoid arthritis of left hand |
M05.549 | Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified hand |
M05.55 | Rheumatoid polyneuropathy with rheumatoid arthritis of hip |
M05.551 | Rheumatoid polyneuropathy with rheumatoid arthritis of right hip |
M05.552 | Rheumatoid polyneuropathy with rheumatoid arthritis of left hip |
M05.559 | Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified hip |
M05.56 | Rheumatoid polyneuropathy with rheumatoid arthritis of knee |
M05.561 | Rheumatoid polyneuropathy with rheumatoid arthritis of right knee |
M05.562 | Rheumatoid polyneuropathy with rheumatoid arthritis of left knee |
M05.569 | Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified knee |
M05.57 | Rheumatoid polyneuropathy with rheumatoid arthritis of ankle and foot |
M05.571 | Rheumatoid polyneuropathy with rheumatoid arthritis of right ankle and foot |
M05.572 | Rheumatoid polyneuropathy with rheumatoid arthritis of left ankle and foot |
M05.579 | Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified ankle and foot |
M05.59 | Rheumatoid polyneuropathy with rheumatoid arthritis of multiple sites |
M05.6 | Rheumatoid arthritis with involvement of other organs and systems |
M05.60 | Rheumatoid arthritis of unspecified site with involvement of other organs and systems |
M05.61 | Rheumatoid arthritis of shoulder with involvement of other organs and systems |
M05.611 | Rheumatoid arthritis of right shoulder with involvement of other organs and systems |
M05.612 | Rheumatoid arthritis of left shoulder with involvement of other organs and systems |
M05.619 | Rheumatoid arthritis of unspecified shoulder with involvement of other organs and systems |
M05.62 | Rheumatoid arthritis of elbow with involvement of other organs and systems |
M05.621 | Rheumatoid arthritis of right elbow with involvement of other organs and systems |
M05.622 | Rheumatoid arthritis of left elbow with involvement of other organs and systems |
M05.629 | Rheumatoid arthritis of unspecified elbow with involvement of other organs and systems |
M05.63 | Rheumatoid arthritis of wrist with involvement of other organs and systems |
M05.631 | Rheumatoid arthritis of right wrist with involvement of other organs and systems |
M05.632 | Rheumatoid arthritis of left wrist with involvement of other organs and systems |
M05.639 | Rheumatoid arthritis of unspecified wrist with involvement of other organs and systems |
M05.64 | Rheumatoid arthritis of hand with involvement of other organs and systems |
M05.641 | Rheumatoid arthritis of right hand with involvement of other organs and systems |
M05.642 | Rheumatoid arthritis of left hand with involvement of other organs and systems |
M05.649 | Rheumatoid arthritis of unspecified hand with involvement of other organs and systems |
M05.65 | Rheumatoid arthritis of hip with involvement of other organs and systems |
M05.651 | Rheumatoid arthritis of right hip with involvement of other organs and systems |
M05.652 | Rheumatoid arthritis of left hip with involvement of other organs and systems |
M05.659 | Rheumatoid arthritis of unspecified hip with involvement of other organs and systems |
M05.66 | Rheumatoid arthritis of knee with involvement of other organs and systems |
M05.661 | Rheumatoid arthritis of right knee with involvement of other organs and systems |
M05.662 | Rheumatoid arthritis of left knee with involvement of other organs and systems |
M05.669 | Rheumatoid arthritis of unspecified knee with involvement of other organs and systems |
M05.67 | Rheumatoid arthritis of ankle and foot with involvement of other organs and systems |
M05.671 | Rheumatoid arthritis of right ankle and foot with involvement of other organs and systems |
M05.672 | Rheumatoid arthritis of left ankle and foot with involvement of other organs and systems |
M05.679 | Rheumatoid arthritis of unspecified ankle and foot with involvement of other organs and systems |
M05.69 | Rheumatoid arthritis of multiple sites with involvement of other organs and systems |
M05.7 | Rheumatoid arthritis with rheumatoid factor without organ or systems involvement |
M05.70 | Rheumatoid arthritis with rheumatoid factor of unspecified site without organ or systems involvement |
M05.71 | Rheumatoid arthritis with rheumatoid factor of shoulder without organ or systems involvement |
M05.711 | Rheumatoid arthritis with rheumatoid factor of right shoulder without organ or systems involvement |
M05.712 | Rheumatoid arthritis with rheumatoid factor of left shoulder without organ or systems involvement |
M05.719 | Rheumatoid arthritis with rheumatoid factor of unspecified shoulder without organ or systems involvement |
M05.72 | Rheumatoid arthritis with rheumatoid factor of elbow without organ or systems involvement |
M05.721 | Rheumatoid arthritis with rheumatoid factor of right elbow without organ or systems involvement |
M05.722 | Rheumatoid arthritis with rheumatoid factor of left elbow without organ or systems involvement |
M05.729 | Rheumatoid arthritis with rheumatoid factor of unspecified elbow without organ or systems involvement |
M05.73 | Rheumatoid arthritis with rheumatoid factor of wrist without organ or systems involvement |
M05.731 | Rheumatoid arthritis with rheumatoid factor of right wrist without organ or systems involvement |
M05.732 | Rheumatoid arthritis with rheumatoid factor of left wrist without organ or systems involvement |
M05.739 | Rheumatoid arthritis with rheumatoid factor of unspecified wrist without organ or systems involvement |
M05.74 | Rheumatoid arthritis with rheumatoid factor of hand without organ or systems involvement |
M05.741 | Rheumatoid arthritis with rheumatoid factor of right hand without organ or systems involvement |
M05.742 | Rheumatoid arthritis with rheumatoid factor of left hand without organ or systems involvement |
M05.749 | Rheumatoid arthritis with rheumatoid factor of unspecified hand without organ or systems involvement |
M05.75 | Rheumatoid arthritis with rheumatoid factor of hip without organ or systems involvement |
M05.751 | Rheumatoid arthritis with rheumatoid factor of right hip without organ or systems involvement |
M05.752 | Rheumatoid arthritis with rheumatoid factor of left hip without organ or systems involvement |
M05.759 | Rheumatoid arthritis with rheumatoid factor of unspecified hip without organ or systems involvement |
M05.76 | Rheumatoid arthritis with rheumatoid factor of knee without organ or systems involvement |
M05.761 | Rheumatoid arthritis with rheumatoid factor of right knee without organ or systems involvement |
M05.762 | Rheumatoid arthritis with rheumatoid factor of left knee without organ or systems involvement |
M05.769 | Rheumatoid arthritis with rheumatoid factor of unspecified knee without organ or systems involvement |
M05.77 | Rheumatoid arthritis with rheumatoid factor of ankle and foot without organ or systems involvement |
M05.771 | Rheumatoid arthritis with rheumatoid factor of right ankle and foot without organ or systems involvement |
M05.772 | Rheumatoid arthritis with rheumatoid factor of left ankle and foot without organ or systems involvement |
M05.779 | Rheumatoid arthritis with rheumatoid factor of unspecified ankle and foot without organ or systems involvement |
M05.79 | Rheumatoid arthritis with rheumatoid factor of multiple sites without organ or systems involvement |
M05.7A | Rheumatoid arthritis with rheumatoid factor of other specified site without organ or systems involvement |
M05.8 | Other rheumatoid arthritis with rheumatoid factor |
M05.80 | Other rheumatoid arthritis with rheumatoid factor of unspecified site |
M05.81 | Other rheumatoid arthritis with rheumatoid factor of shoulder |
M05.811 | Other rheumatoid arthritis with rheumatoid factor of right shoulder |
M05.812 | Other rheumatoid arthritis with rheumatoid factor of left shoulder |
M05.819 | Other rheumatoid arthritis with rheumatoid factor of unspecified shoulder |
M05.82 | Other rheumatoid arthritis with rheumatoid factor of elbow |
M05.821 | Other rheumatoid arthritis with rheumatoid factor of right elbow |
M05.822 | Other rheumatoid arthritis with rheumatoid factor of left elbow |
M05.829 | Other rheumatoid arthritis with rheumatoid factor of unspecified elbow |
M05.83 | Other rheumatoid arthritis with rheumatoid factor of wrist |
M05.831 | Other rheumatoid arthritis with rheumatoid factor of right wrist |
M05.832 | Other rheumatoid arthritis with rheumatoid factor of left wrist |
M05.839 | Other rheumatoid arthritis with rheumatoid factor of unspecified wrist |
M05.84 | Other rheumatoid arthritis with rheumatoid factor of hand |
M05.841 | Other rheumatoid arthritis with rheumatoid factor of right hand |
M05.842 | Other rheumatoid arthritis with rheumatoid factor of left hand |
M05.849 | Other rheumatoid arthritis with rheumatoid factor of unspecified hand |
M05.85 | Other rheumatoid arthritis with rheumatoid factor of hip |
M05.851 | Other rheumatoid arthritis with rheumatoid factor of right hip |
M05.852 | Other rheumatoid arthritis with rheumatoid factor of left hip |
M05.859 | Other rheumatoid arthritis with rheumatoid factor of unspecified hip |
M05.86 | Other rheumatoid arthritis with rheumatoid factor of knee |
M05.861 | Other rheumatoid arthritis with rheumatoid factor of right knee |
M05.862 | Other rheumatoid arthritis with rheumatoid factor of left knee |
M05.869 | Other rheumatoid arthritis with rheumatoid factor of unspecified knee |
M05.87 | Other rheumatoid arthritis with rheumatoid factor of ankle and foot |
M05.871 | Other rheumatoid arthritis with rheumatoid factor of right ankle and foot |
M05.872 | Other rheumatoid arthritis with rheumatoid factor of left ankle and foot |
M05.879 | Other rheumatoid arthritis with rheumatoid factor of unspecified ankle and foot |
M05.89 | Other rheumatoid arthritis with rheumatoid factor of multiple sites |
M05.8A | Other rheumatoid arthritis with rheumatoid factor of other specified site |
M05.9 | Rheumatoid arthritis with rheumatoid factor, unspecified |
M06 | Other rheumatoid arthritis |
M06.0 | Rheumatoid arthritis without rheumatoid factor |
M06.00 | Rheumatoid arthritis without rheumatoid factor, unspecified site |
M06.01 | Rheumatoid arthritis without rheumatoid factor, shoulder |
M06.011 | Rheumatoid arthritis without rheumatoid factor, right shoulder |
M06.012 | Rheumatoid arthritis without rheumatoid factor, left shoulder |
M06.019 | Rheumatoid arthritis without rheumatoid factor, unspecified shoulder |
M06.02 | Rheumatoid arthritis without rheumatoid factor, elbow |
M06.021 | Rheumatoid arthritis without rheumatoid factor, right elbow |
M06.022 | Rheumatoid arthritis without rheumatoid factor, left elbow |
M06.029 | Rheumatoid arthritis without rheumatoid factor, unspecified elbow |
M06.03 | Rheumatoid arthritis without rheumatoid factor, wrist |
M06.031 | Rheumatoid arthritis without rheumatoid factor, right wrist |
M06.032 | Rheumatoid arthritis without rheumatoid factor, left wrist |
M06.039 | Rheumatoid arthritis without rheumatoid factor, unspecified wrist |
M06.04 | Rheumatoid arthritis without rheumatoid factor, hand |
M06.041 | Rheumatoid arthritis without rheumatoid factor, right hand |
M06.042 | Rheumatoid arthritis without rheumatoid factor, left hand |
M06.049 | Rheumatoid arthritis without rheumatoid factor, unspecified hand |
M06.05 | Rheumatoid arthritis without rheumatoid factor, hip |
M06.051 | Rheumatoid arthritis without rheumatoid factor, right hip |
M06.052 | Rheumatoid arthritis without rheumatoid factor, left hip |
M06.059 | Rheumatoid arthritis without rheumatoid factor, unspecified hip |
M06.06 | Rheumatoid arthritis without rheumatoid factor, knee |
M06.061 | Rheumatoid arthritis without rheumatoid factor, right knee |
M06.062 | Rheumatoid arthritis without rheumatoid factor, left knee |
M06.069 | Rheumatoid arthritis without rheumatoid factor, unspecified knee |
M06.07 | Rheumatoid arthritis without rheumatoid factor, ankle and foot |
M06.071 | Rheumatoid arthritis without rheumatoid factor, right ankle and foot |
M06.072 | Rheumatoid arthritis without rheumatoid factor, left ankle and foot |
M06.079 | Rheumatoid arthritis without rheumatoid factor, unspecified ankle and foot |
M06.08 | Rheumatoid arthritis without rheumatoid factor, vertebrae |
M06.09 | Rheumatoid arthritis without rheumatoid factor, multiple sites |
M06.0A | Rheumatoid arthritis without rheumatoid factor, other specified site |
M06.8 | Other specified rheumatoid arthritis |
M06.80 | Other specified rheumatoid arthritis, unspecified site |
M06.81 | Other specified rheumatoid arthritis, shoulder |
M06.811 | Other specified rheumatoid arthritis, right shoulder |
M06.812 | Other specified rheumatoid arthritis, left shoulder |
M06.819 | Other specified rheumatoid arthritis, unspecified shoulder |
M06.82 | Other specified rheumatoid arthritis, elbow |
M06.821 | Other specified rheumatoid arthritis, right elbow |
M06.822 | Other specified rheumatoid arthritis, left elbow |
M06.829 | Other specified rheumatoid arthritis, unspecified elbow |
M06.83 | Other specified rheumatoid arthritis, wrist |
M06.831 | Other specified rheumatoid arthritis, right wrist |
M06.832 | Other specified rheumatoid arthritis, left wrist |
M06.839 | Other specified rheumatoid arthritis, unspecified wrist |
M06.84 | Other specified rheumatoid arthritis, hand |
M06.841 | Other specified rheumatoid arthritis, right hand |
M06.842 | Other specified rheumatoid arthritis, left hand |
M06.849 | Other specified rheumatoid arthritis, unspecified hand |
M06.85 | Other specified rheumatoid arthritis, hip |
M06.851 | Other specified rheumatoid arthritis, right hip |
M06.852 | Other specified rheumatoid arthritis, left hip |
M06.859 | Other specified rheumatoid arthritis, unspecified hip |
M06.86 | Other specified rheumatoid arthritis, knee |
M06.861 | Other specified rheumatoid arthritis, right knee |
M06.862 | Other specified rheumatoid arthritis, left knee |
M06.869 | Other specified rheumatoid arthritis, unspecified knee |
M06.87 | Other specified rheumatoid arthritis, ankle and foot |
M06.871 | Other specified rheumatoid arthritis, right ankle and foot |
M06.872 | Other specified rheumatoid arthritis, left ankle and foot |
M06.879 | Other specified rheumatoid arthritis, unspecified ankle and foot |
M06.88 | Other specified rheumatoid arthritis, vertebrae |
M06.89 | Other specified rheumatoid arthritis, multiple sites |
M06.8A | Other specified rheumatoid arthritis, other specified site |
M06.9 | Rheumatoid arthritis, unspecified |
Formulary Reference Tool